Updated Efficacy and Safety Results of Patients Receiving Selected 100mg Bezuclastinib Dose and Participating in the Open-Label Extension of Summit: A Randomized, Double-Blind, Placebo Controlled Phase 2 Clinical Trial of Bezuclastinib in Adult Patients with Nonadvanced Systemic Mastocytosis
Year: 2024
Type: conference-abstract
Source: Blood
Authors: Lindsay A.M. Rein, Daniel J. DeAngelo, Brian Modena, Stephen Oh, Bulai Livideanu Cridtina, Celalettin Ustun, Nathan Boggs, Michael Manning, Anthony M. Hunter, Cem Akin, Arnold Kirshenbaum, Ingunn Dybedal, Cecilia Y. Arana Yi, Richard Herrscher, Mariana Castells, Frederick Lansigan, Tracy I. George, Jay Patel, Lei Sun, Nisha Shah, Jenna Zhang, Amanda Pilla, Priya Singh, Marcus Carden, Frank Siebenhaar, Prithviraj Bose
Institutions: Duke University, Duke Cancer Institute, Dana-Farber Cancer Institute, Washington University in St. Louis, Centre Hospitalier Universitaire de Toulouse, Rush University Medical Center, Walter Reed National Military Medical Center, Emory University, Winship Cancer Institute, University of Michigan, Northwest Clinical Research Center, Gwinnett Dermatology, Oslo University Hospital, Mayo Clinic in Arizona, Brigham and Women's Hospital, Dartmouth–Hitchcock Medical Center, University of Utah, ARUP Laboratories (United States), Cogent Biosciences (United States), Charité - Universitätsmedizin Berlin, The University of Texas MD Anderson Cancer Center
Language: English
Topic: Mast cells and histamine
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4405039430